HB0056 / Zhejiang Huahai Pharma, Huaota Biopharm, Huabo Biopharmaceutical Technology - LARVOL DELTA

Dual Blockade of TSLP and IL11 with a bispecific antibody: A Promising Strategy for the Treatment of Asthma and Other Airway Disorders (EAACI 2026) - "In the TSLP inhibition assay, HX16118 inhibited TSLP signaling with a sub-nanomolar IC₅₀, outperforming Tezepelumab...Importantly, in hyper-IL11 trans-signaling assays, HX16118 (IC₅₀ ~1.04 nM) displayed markedly enhanced potency compared to both HB0056 and 9MW3811 (~18.60 nM)...Accordingly, HX16118 holds strong potential for the treatment of asthma and other inflammatory airway diseases. Preclinical development of HX16118 is currently underway."

Bispecific • Dermatitis • Immunology • Inflammation • CRLF2 • STAT3 • STAT5 • TSLP

...Huaotai HB0056 (TSLP/IL-11 Bispecific Antibody) Completes Enrollment and Dosing of First Patient for Asthma Indication [Google translation] (Sina Corp)

Trial status • Asthma

Clinical trial of new asthma drug: TSLP/IL-11 nano dual-antibody new drug HB0056 injection [Google translation] (Sohu.com) - "HB0056 is a bispecific antibody with anti-TSLP humanized monoclonal antibody as the parent antibody and anti-IL-11 single-chain nanobody connected at the N-terminus...Study drug: HB0056 injection (Phase Ib/II); Registration number: CTR20252580; Trial type: Controlled trial (vs placebo); Indications: Asthma...Patients who have received medium-to-high-dose ICS (≥250 μg fluticasone propionate dry powder equivalent daily total dose) combined with at least one controller drug (such as LABA, LTRA, theophylline, LAMA, sodium cromolyn, etc.) for ≥3 consecutive months before screening, and maintained a stable treatment regimen and dosage for ≥1 month before screening....At least one acute asthma attack occurred within 12 months before screening."

Trial status • Asthma • Immunology • Inflammation

Huahai Pharmaceutical (600521.SH)’s subsidiary drug HB0056 injection obtained drug clinical trial approval (Investing.com) - "According to the Zhitong Finance APP, Huahai Pharmaceutical (600521.SH) announced that recently, the company's subsidiaries Shanghai Huaotai Biopharmaceutical Co., Ltd. (referred to as 'Huaotai') and Huabo Biotechnology (Shanghai) Co., Ltd. (a wholly-owned subsidiary of Huaotai, referred to as 'Huabo Bio') received the 'Drug Clinical Trial Approval Notice' for HB0056 Injection approved and issued by the State Drug Administration (referred to as 'NMPA'), and the drug is indicated for asthma."

New trial • Asthma